• Mashup Score: 1

    The use of extracorporeal cardiopulmonary resuscitation (ECPR) to restore circulation during cardiac arrest is a time-critical, resource-intensive intervention of unproven efficacy. The current COVID-19 pandemic has brought additional complexity and significant barriers to the ongoing provision and implementation of ECPR services. The logistics of patient selection, expedient cannulation,…

    Tweet Tweets with this article
    • #CritCare #OpenAccess https://t.co/zqyeEbaFIu Challenges to the ongoing provision and implementation of ECPR services during #COVID_19 pandemics #FOAMed #FOAMcc #BMC #ICU @jlvincen @ISICEM #IntensiveCare #coronavirus #infection #cardiopulmonary #resuscitation #safety https://t.co/fhCAeeg7z4

  • Mashup Score: 1

    As you were browsing www.clinicaloncology.com something about your browser made us think you were a bot. There are a few reasons this might happen: You’re a power user moving through this website with super-human speed. You’ve disabled JavaScript in your web browser. A third-party browser plugin, such…

    Tweet Tweets with this article
    • A carfilzomib-based regimen did not improve outcomes and was associated with more #cardiopulmonary and #renal adverse events. https://t.co/VFammla81l @ASCO @myelomaMD #carfilzomib #myeloma #multiplemyeloma

  • Mashup Score: 0

    Sickle cell disease (SCD) and its variants are genetic disorders resulting from the presence of a mutated form of hemoglobin, hemoglobin S (HbS) (see the image below). The most common form of SCD found in North America is homozygous HbS disease (HbSS), an autosomal recessive disorder first described by Herrick in 1910.

    Tweet Tweets with this article
    • A summary of key guidelines on the screening, diagnosis, and management of #cardiopulmonary and renal complications of sickle cell disease updates this clinical tool. https://t.co/28dfxa1tQ0 https://t.co/pENOXRxcXa